Oruka Therapeutics, Inc. Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.

ORKA

Clasificación en acciones #3302
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Precio por acción
$80.01
Última sincronización: 2026-10-21
Capitalización bursátil
$5.30B
Cambio (1 día)
1.16%
Cambio (1 año)
200.21%
País
US
Comercio Oruka Therapeutics, Inc. (ORKA)

Categoría

Healthcare
Ratio P/B de Oruka Therapeutics, Inc. (ORKA)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Oruka Therapeutics, Inc., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Oruka Therapeutics, Inc. desde 2005 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
2024 0.85 -89.28%
2023 7.94 -19.22%
2022 9.83 39.93%
2021 7.03 44.25%
2020 4.87 391.44%
2019 0.99 30.86%
2018 0.76 -44.72%
2017 1.37 17.70%
2016 1.16 51.58%
2015 0.77 -41.86%
2014 1.32 42.00%
2013 0.93 -46.63%
2012 1.74 -0.42%
2011 1.75 -56.04%
2010 3.98 27.67%
2009 3.12 -7,157.47%
2008 -0.04 -103.06%
2007 1.44 -51.05%
2006 2.95 -50.04%
2005 5.90 0.00%
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.251 -
US
13.2547 -
US
4.208 -
AU
6.1824 -
NL
- -
CH